CYRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

42.93M

-27.88%

-0.217

-49.2%

44.54M

+8.52%

-0.138

-64.14%

48.63M

+6.98%

-0.135

-44.34%

Estimates Revision

The market is revising Upward the revenue expectations for Cryoport, Inc. (CYRX) for FY2025, with the revenue forecasts being adjusted by 1.43% over the past three months. During the same period, the stock price has changed by 2.78%.

Revenue Estimates for FY2025

Revise Upward

+1.43%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.59%

In Past 3 Month

Stock Price

Go Up

+2.78%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast CYRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYRX is 13.63 USD with a low forecast of 12.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 9.240

Low

12.00

Averages

13.63

High

15.00

Current: 9.240

Low

12.00

Averages

13.63

High

15.00

UBS

Buy

maintain

$11

2025-11-05

Reason

UBS

Price Target

$11

2025-11-05

maintain

Buy

Reason

UBS raised the firm's price target on Cryoport to $12.50 from $11 and keeps a Buy rating on the shares.

BTIG

NULL -> Buy

maintain

$10 -> $15

2025-09-18

Reason

BTIG

Price Target

$10 -> $15

2025-09-18

maintain

NULL -> Buy

Reason

BTIG raised the firm's price target on Cryoport to $15 from $10 and keeps a Buy rating on the shares. The stock has been under some pressure over the past 2 years, but this is likely due to worries around the Inflation Reduction Act, tariffs, Most Favored Nation, and drug pricing reform risk, and the market appears to be turning the corner, the analyst tells investors in a research note. Cryoport's gross margin and Product revenue growth are also showing good improvement, and the company has well over $400M of cash, the firm added.

KeyBanc

Sector Weight -> Overweight

upgrade

$15

2025-08-06

Reason

KeyBanc

Price Target

$15

2025-08-06

upgrade

Sector Weight -> Overweight

Reason

KeyBanc upgraded Cryoport to Overweight from Sector Weight with a $15 price target following the Q2 beat. The firm believes the cell and gene therapy market is gaining momentum as FDA approved therapies, particularly CAR-Ts, emerge as a significant growth driver. The analyst now has visibility into more consistent results going forward for Cryoport.

Leerink

Market Perform -> Outperform

upgrade

$10 -> $16

2025-08-06

Reason

Leerink

Price Target

$10 -> $16

2025-08-06

upgrade

Market Perform -> Outperform

Reason

Leerink upgraded Cryoport to Outperform from Market Perform with a price target of $16, up from $10. The firm believes the company is positioned to beat estimates on continued cell and gene therapy market services strength. The analyst is also encouraged by recent stabilization in the company's MVE business. Leerink sees "beats and raises" well into 2026 for Cryoport.

Stephens

NULL

Overweight

initiated

$13

2025-07-21

Reason

Stephens

Price Target

$13

2025-07-21

initiated

NULL

Overweight

Reason

Stephens resumed coverage of Cryoport with an Overweight rating and $13 price target. The firm says the company has a large platform of supply chain solutions for the growing cell and gene therapy industry. Cryoport will benefit as the macro environment normalizes and therapies move through the clinical pipeline, the analyst tells investors in a research note.

BTIG

Buy

downgrade

$13 -> $10

2025-07-07

Reason

BTIG

Price Target

$13 -> $10

2025-07-07

downgrade

Buy

Reason

BTIG lowered the firm's price target on Cryoport to $10 from $13 and keeps a Buy rating on the shares following the firm's survey of biopharma manufacturers. R&D Services budgets will likely face the most risk and headwinds over the next 2 years, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Cryoport Inc (CYRX.O) is -14.52, compared to its 5-year average forward P/E of -90.96. For a more detailed relative valuation and DCF analysis to assess Cryoport Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-90.96

Current PE

-14.52

Overvalued PE

104.33

Undervalued PE

-286.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

7.44

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

128.37

Undervalued EV/EBITDA

-113.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

5.17

Current PS

0.00

Overvalued PS

9.01

Undervalued PS

1.32

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CYRX News & Events

Events Timeline

No data

News

3.5

11-06Newsfilter

Cryoport Systems Receives 2025 BioTech Breakthrough Award for "BioServices Innovation of the Year"

3.5

11-06Globenewswire

Cryoport Systems Receives 2025 BioTech Breakthrough Award for "BioServices Innovation of the Year"

9.5

11-05NASDAQ.COM

CryoPort, Inc. (CYRX) Announces Q3 Loss but Exceeds Revenue Projections

People Also Watch

Frequently Asked Questions

What is Cryoport Inc (CYRX) stock price today?

The current price of CYRX is 9.24 USD — it has decreased -1.7 % in the last trading day.

What is Cryoport Inc (CYRX)'s business?

Cryoport, Inc. provides temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. The Company supports biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products. Its integrated supply chain platform includes the Cryoportal Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems. The Company's segments include Life Sciences Services and Life Sciences Products. The Company's Life Sciences Services segment provides cryogenic biostorage within the life science industry through direct sales. Its Life Sciences Products segment manufactures and sells cryogenic freezers, cryogenic dewars and accessories within the life science industry through direct sales or a distribution network.

What is the price predicton of CYRX Stock?

What is Cryoport Inc (CYRX)'s revenue for the last quarter?

Cryoport Inc revenue for the last quarter amounts to 44.23M USD, increased 15.44 % YoY.

What is Cryoport Inc (CYRX)'s earnings per share (EPS) for the last quarter?

Cryoport Inc. EPS for the last quarter amounts to -0.18 USD, increased 800.00 % YoY.

What changes have occurred in the market's expectations for Cryoport Inc (CYRX)'s fundamentals?

How many employees does Cryoport Inc (CYRX). have?

Cryoport Inc (CYRX) has 1090 emplpoyees as of December 16 2025.

What is Cryoport Inc (CYRX) market cap?

Today CYRX has the market capitalization of 462.64M USD.